To examine the appearance of Aβ plaques and tau NFTs as positive controls, we performed immunohistochemistry with post-mortem sections from the temporal lobe of a human AD patient and TG APP_SDI and TG mice expressing the human tau protein. This evidence concerns the gene MAPT and Alzheimer disease.